Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.
Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients
CALCAGNO, Andrea;
2015-01-01
Abstract
Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
19 DD535-16.pdf
file disponibile solo agli amministratori
Licenza:
DRM non definito
Dimensione
424.79 kB
Formato
Adobe PDF
|
424.79 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
